Vyndaqel
Europe approves first treatment for transthyretin amyloidosis in cardiomyopathy patients: Pfizer’s Vyndaqel
February 19, 2020Research and Development, Sales and Marketing Europe, Pfizer, Vyndaqel, pharma, transthyretin amyloidosis
The European Commission (EC) has awarded marketing approval to Pfizer’s Vyndaqel (tafamidis), it has emerged, for the treatment of wild-type …
Pfizer’s Vyndaqel scores CHMP support for transthyretin amyloidosis in cardiomyopathy patients
December 16, 2019Sales and Marketing Pfizer, Vyndaqel, pharma
Pfizer’s once-daily 61mg oral capsule formulation of Vyndaqel (tafamidis) has secured a positive opinion from the European Medicines Agency’s (EMA) …
FDA approves first two drugs for transthyretin amyloid cardiomyopathy
May 7, 2019Manufacturing and Production, Sales and Marketing FDA, Pfizer, US, Vyndamax, Vyndaqel, pharma
The FDA has approved its first two therapies for the treatment of cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM), …
Latest content
FibroFind appoints Lee Borthwick as CEO
July 21, 2026
